REG - Advanced Oncotherapy - Total Voting Rights

Advanced OncotherapyAnnouncement

29/05/2020 17:00

RNS Number : 2626O
  
Advanced Oncotherapy PLC
  
29 May 2020
  
 

29 May 2020
 
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
 
Total Voting Rights
 
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that the Company's issued share capital as at the date of this announcement comprises 306,371,241 ordinary shares of 25p each, with one voting right per share ("Ordinary Shares"). The Company does not hold any ordinary shares in treasury and therefore the total number of Ordinary Shares with voting rights in the Company is 306,371,241.
 
The above figure of 306,371,241 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
 
 



Advanced Oncotherapy plc


www.avoplc.com




Dr. Michael Sinclair, Executive Chairman


Tel: +44 (0) 20 3617 8728




Nicolas Serandour, CEO
 
 


















Allenby Capital Limited (Nomad & Broker)








Nick Athanas / Liz Kirchner / Nicholas Chambers
 
 


Tel: +44 (0) 20 3328 5656














FTI Consulting (Financial PR & IR)


advancedoncotherapy@fticonsulting.com




Simon Conway / Rob Winder


Tel: +44 (0) 20 3727 1000



 
 
Notes for Editors
 
About Advanced Oncotherapy Plc www.avoplc.com
 
Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.
 
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.
 
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
TVREADSPALNEEFA